These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 9072005)

  • 21. Proteoglycans and WT1 as markers for distinguishing adenocarcinoma, epithelioid mesothelioma, and benign mesothelium.
    Gulyás M; Hjerpe A
    J Pathol; 2003 Apr; 199(4):479-87. PubMed ID: 12635139
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidermal growth factor receptor and transforming growth factor alpha expression in papillary and nonpapillary renal cell carcinoma: correlation with metastatic behavior and prognosis.
    Uhlman DL; Nguyen P; Manivel JC; Zhang G; Hagen K; Fraley E; Aeppli D; Niehans GA
    Clin Cancer Res; 1995 Aug; 1(8):913-20. PubMed ID: 9816062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High Wilms' tumour gene (WT1) expression and low mitotic count are independent predictors of survival in diffuse peritoneal mesothelioma.
    Scattone A; Serio G; Marzullo A; Nazzaro P; Corsi F; Cocca MP; Mattoni M; Punzi A; Gentile M; Buonadonna AL; Pennella A
    Histopathology; 2012 Feb; 60(3):472-81. PubMed ID: 22276610
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Osteopontin is linked to p65 and MMP-9 expression in pulmonary adenocarcinoma but not in malignant pleural mesothelioma.
    Frey AB; Wali A; Pass H; Lonardo F
    Histopathology; 2007 May; 50(6):720-6. PubMed ID: 17493236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of Wilms' tumor suppressor in the liver with cirrhosis: relation to hepatocyte nuclear factor 4 and hepatocellular function.
    Berasain C; Herrero JI; García-Trevijano ER; Avila MA; Esteban JI; Mato JM; Prieto J
    Hepatology; 2003 Jul; 38(1):148-57. PubMed ID: 12829997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma.
    Amin KM; Litzky LA; Smythe WR; Mooney AM; Morris JM; Mews DJ; Pass HI; Kari C; Rodeck U; Rauscher FJ
    Am J Pathol; 1995 Feb; 146(2):344-56. PubMed ID: 7856747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurotensin expression and outcome of malignant pleural mesothelioma.
    Alifano M; Loi M; Camilleri-Broet S; Dupouy S; Régnard JF; Forgez P
    Biochimie; 2010 Feb; 92(2):164-70. PubMed ID: 19932148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of genes coding for proteoglycans and Wilms' tumour susceptibility gene 1 (WT1) by variously differentiated benign human mesothelial cells.
    Gulyás M; Dobra K; Hjerpe A
    Differentiation; 1999 Oct; 65(2):89-96. PubMed ID: 10550542
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunoreactivity for p53 protein in malignant mesothelioma and non-neoplastic mesothelium.
    Ramael M; Lemmens G; Eerdekens C; Buysse C; Deblier I; Jacobs W; van Marck E
    J Pathol; 1992 Dec; 168(4):371-5. PubMed ID: 1484318
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunoreactivity for c-fos and c-myc protein with the monoclonal antibodies 14E10 and 6E10 in malignant mesothelioma and non-neoplastic mesothelium of the pleura.
    Ramael M; Van den Bossche J; Buysse C; Deblier I; Segers K; Van Marck E
    Histol Histopathol; 1995 Jul; 10(3):639-43. PubMed ID: 7579812
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin-like growth factor type 1 receptor expression correlates to good prognosis in highly malignant soft tissue sarcoma.
    Ahlén J; Wejde J; Brosjö O; von Rosen A; Weng WH; Girnita L; Larsson O; Larsson C
    Clin Cancer Res; 2005 Jan; 11(1):206-16. PubMed ID: 15671548
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma.
    Kumar-Singh S; Vermeulen PB; Weyler J; Segers K; Weyn B; Van Daele A; Dirix LY; Van Oosterom AT; Van Marck E
    J Pathol; 1997 Jun; 182(2):211-6. PubMed ID: 9274533
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors.
    Kothmaier H; Quehenberger F; Halbwedl I; Morbini P; Demirag F; Zeren H; Comin CE; Murer B; Cagle PT; Attanoos R; Gibbs AR; Galateau-Salle F; Popper HH
    Thorax; 2008 Apr; 63(4):345-51. PubMed ID: 18086752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical significance of the expression of tumor-associated antigen, RCAS1, and its soluble protein in pleural fluid in malignant mesothelioma.
    Hiraki A; Aoe K; Murakami T; Nakamura Y; Yamazaki K; Sueoka N; Taguchi K; Kamei T; Maeda T; Takeyama H; Kishimoto T; Nishimura M; Sugi K
    Oncol Rep; 2005 Aug; 14(2):357-62. PubMed ID: 16012715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro.
    Cole GW; Alleva AM; Reddy RM; Maxhimer JB; Zuo J; Schrump DS; Nguyen DM
    J Thorac Cardiovasc Surg; 2005 May; 129(5):1010-7. PubMed ID: 15867774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of inducible nitric oxide synthase in healthy pleura and in malignant mesothelioma.
    Soini Y; Kahlos K; Puhakka A; Lakari E; Säily M; Pääkkö P; Kinnula V
    Br J Cancer; 2000 Oct; 83(7):880-6. PubMed ID: 10970689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reactivity of integrin-linked kinase in human mesothelial cell proliferation.
    Watzka SB; Setinek U; Huber M; Cantonati H; Lax F; Watson S; Weigel G; Müller MR
    Interact Cardiovasc Thorac Surg; 2008 Feb; 7(1):107-10. PubMed ID: 18048409
    [TBL] [Abstract][Full Text] [Related]  

  • 38. L1CAM, INP10, P-cadherin, tPA and ITGB4 over-expression in malignant pleural mesotheliomas revealed by combined use of cDNA and tissue microarray.
    Kettunen E; Nicholson AG; Nagy B; Wikman H; Seppänen JK; Stjernvall T; Ollikainen T; Kinnula V; Nordling S; Hollmén J; Anttila S; Knuutila S
    Carcinogenesis; 2005 Jan; 26(1):17-25. PubMed ID: 15447976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma.
    Edwards JG; Swinson DE; Jones JL; Waller DA; O'Byrne KJ
    Lung Cancer; 2006 Dec; 54(3):399-407. PubMed ID: 17049671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of E2F-4 in invasive breast carcinomas is associated with poor prognosis.
    Rakha EA; Pinder SE; Paish EC; Robertson JF; Ellis IO
    J Pathol; 2004 Jul; 203(3):754-61. PubMed ID: 15221934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.